XTX Topco Ltd Takes Position in STAAR Surgical Company (NASDAQ:STAA)

XTX Topco Ltd acquired a new position in STAAR Surgical Company (NASDAQ:STAA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 31,835 shares of the medical instruments supplier's stock, valued at approximately $561,000. XTX Topco Ltd owned 0.06% of STAAR Surgical as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Linden Thomas Advisory Services LLC grew its stake in STAAR Surgical by 3.0% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 20,978 shares of the medical instruments supplier's stock worth $370,000 after buying an additional 603 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in STAAR Surgical by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,123 shares of the medical instruments supplier's stock worth $683,000 after buying an additional 1,044 shares in the last quarter. MetLife Investment Management LLC grew its stake in STAAR Surgical by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 30,396 shares of the medical instruments supplier's stock worth $738,000 after buying an additional 1,796 shares in the last quarter. Bridgefront Capital LLC grew its stake in STAAR Surgical by 27.2% in the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock worth $262,000 after buying an additional 2,306 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in STAAR Surgical by 6.9% in the 4th quarter. Deutsche Bank AG now owns 45,193 shares of the medical instruments supplier's stock worth $1,098,000 after buying an additional 2,932 shares in the last quarter. Institutional investors own 96.70% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on STAA shares. Canaccord Genuity Group boosted their price target on shares of STAAR Surgical from $20.00 to $28.00 and gave the stock a "hold" rating in a research note on Wednesday. Piper Sandler upgraded shares of STAAR Surgical to a "hold" rating in a research note on Wednesday, June 18th. Mizuho increased their price target on shares of STAAR Surgical from $17.00 to $18.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 16th. Stifel Nicolaus set a $28.00 price objective on shares of STAAR Surgical and gave the company a "hold" rating in a research note on Thursday. Finally, Wells Fargo & Company assumed coverage on shares of STAAR Surgical in a research note on Monday, April 21st. They set an "equal weight" rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating and ten have given a hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $20.67.

STAAR Surgical Stock Performance

Shares of STAAR Surgical stock traded up $0.31 on Friday, hitting $27.26. 2,412,737 shares of the company traded hands, compared to its average volume of 3,019,908. The stock has a market capitalization of $1.35 billion, a P/E ratio of -14.12 and a beta of 0.61. STAAR Surgical Company has a 52 week low of $13.50 and a 52 week high of $40.81. The business has a 50-day simple moving average of $18.23 and a 200 day simple moving average of $18.41.

STAAR Surgical announced that its board has initiated a stock repurchase plan on Friday, May 16th that authorizes the company to buyback $30.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 3.2% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its stock is undervalued.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.